(Reuters) – Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals’ add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
The panel voted 13 to 3 against recommending the drug, chemically known as sotagliflozin.
(Reporting by Sneha S K and Sruthi Narasimha Chari in Bengaluru; Editing by Shailesh Kuber)
